Cited by 276Bacterial Infections and VaccinesNeonatal and Maternal InfectionsMicrobial infections and disease research

The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.

Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study

Parikh, Sydel R, Andrews, Nick J, Beebeejaun, Kazim, Campbell, Helen, Ribeiro, Sonia, Ward, Charlotte, White, Joanne M, Borrow, Ray, Ramsay, Mary E, Ladhani, Shamez N·2016·The Lancet

DOI 10.1016/s0140-6736(16)31921-3

Open this paper in CoChat — free account

Abstract

Background In September, 2015, the UK became the first country to introduce the multicomponent group B meningococcal (MenB) vaccine (4CMenB, Bexsero) into a publicly funded national immunisation programme. A reduced two-dose priming schedule was offered to infants at 2 months and 4 months, alongside an opportunistic catch-up for 3 month and 4 month olds. 4CMenB was predicted to protect against 73-88% of MenB strains. We aimed to assess the effectiveness and impact of 4CMenB in vaccine-eligible infants in England.Methods Public Health England (PHE) undertakes enhanced surveillance of meningococcal disease through a combination of clinical, public health, and laboratory reporting. Laboratory-confirmed cases of meningococcal disease are followed up with PHE local health protection teams, general practitioners, and hospital clinicians to collect demographic data, vaccination history, clinical presentation, and outcome. For cases diagnosed between Sept 1, 2015, and June 30, 2016, vaccine effectiveness was assessed using the screening method. Impact was assessed by comparing numbers of cases of MenB in vaccine-eligible children to equivalent cohorts in the previous 4 years and to cases in vaccine-ineligible children.Findings Coverage of 4CMenB in infants eligible for routine vaccination was high, achieving 95·5% for one dose and 88·6% for two doses by 6 months of age. Two-dose vaccine effectiveness was 82·9% (95% CI 24·1-95·2) against all MenB cases, equivalent to a vaccine effectiveness of 94·2% against the highest predicted MenB strain coverage of 88%. Compared with the prevaccine period, there was a 50% incidence rate ratio (IRR) reduction in MenB cases in the vaccine-eligible cohort (37 cases vs average 74 cases; IRR 0·50 [95% CI 0·36-0·71]; p=0·0001), irrespective of the infants' vaccination status or predicted MenB strain coverage. Similar reductions were observed even after adjustment for disease trends in vaccine-eligible and vaccine-ineligible children.Interpretation The two-dose 4CMenB priming schedule was highly effective in preventing MenB disease in infants. Cases in vaccine-eligible infants halved in the first 10 months of the programme. While ongoing national surveillance will continue to monitor the longer-term impact of the programme, these findings represent a step forward in the battle against meningococcal disease and will help reassure that the vaccine protects against this deadly infection.Funding Public Health England.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(16)31921-3

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens
Serruto, D., Bottomley, M. J., Ram, S., Giuliani, M. M., & Rappuoli, R. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.033 · Cited by 405
Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines
Donnelly, J., Medini, D., Boccadifuoco, G., Biolchi, A., Ward, J. I., Frasch, C. E., Moxon, E. R., Stella, M., Comanducci, M., Bambini, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013758107 · Cited by 296
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment
Vogel, U. F., Taha, M., Vázquez, J. A., Findlow, J., Claus, H., Stefanelli, P., Caugant, D. A., Kriz, P., Abad, R., Bambini, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70006-9 · Cited by 283
Self-citation
Estimation of Vaccine Effectiveness Using the Screening Method
Farrington, P. (1993) · International Journal of Epidemiology · doi:10.1093/ije/22.4.742 · Cited by 261
Advances in the Development of Vaccines againstNeisseria meningitidis
Tan, L., Carlone, G. M., & Borrow, R. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0906357 · Cited by 233
Self-citation
Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins
Cartwright, K. A. V., Morris, R., Rümke, H. C., Fox, A., Borrow, R., Begg, N. T., Richmond, P., & POOLMAN, J. T. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00044-4 · Cited by 176
Self-citation
Meningococcal C conjugate vaccine: the experience in England and Wales
Campbell, H., Borrow, R., Salisbury, D., & Miller, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.067 · Cited by 168
Self-citation
Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study
Christensen, H., Trotter, C. L., Hickman, M., & Edmunds, W. J. (2014) · BMJ · doi:10.1136/bmj.g5725 · Cited by 142
Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage
Frosi, G., Biolchi, A., Sapio, M. L., Rigat, F., Gilchrist, S., Lucidarme, J., Findlow, J., Borrow, R., Pizza, M., Giuliani, M. M., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.08.006 · Cited by 137
Self-citation
Bexsero® chronicle
Vernikos, G. S., & Medini, D. (2014) · Pathogens and Global Health · doi:10.1179/2047773214y.0000000162 · Cited by 104

Show all 18 references

Sorted by citations

The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination
Parikh, S. R., Campbell, H., Bettinger, J. A., Harrison, L. H., Marshall, H. S., Martinón‐Torres, F., Sáfadi, M. A. P., Shao, Z., Zhu, B., von Gottberg, A., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.05.079 · Cited by 306
Self-citation
Technologies to address antimicrobial resistance
Baker, S. J., Payne, D. J., Rappuoli, R., & Gregorio, E. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717160115 · Cited by 219
Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024
López‐Lacort, M., Muñoz-Quiles, C., Mira‐Iglesias, A., López‐Labrador, F. X., Mengual‐Chuliá, B., Fernández-García, C., Carballido‐Fernández, M., Caplliure, A. P., Mollar‐Maseres, J., Shalabi-Benavent, M. J., et al. (2024) · Eurosurveillance · doi:10.2807/1560-7917.es.2024.29.6.2400046 · Cited by 216
Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England
Ladhani, S. N., Andrews, N. J., Parikh, S. R., Campbell, H. J., White, J. M., Edelstein, M. L., Bai, X., Lucidarme, J., Borrow, R., & Ramsay, M. E. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1901229 · Cited by 215
Self-citation
The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations
Acevedo, R., Bai, X., Borrow, R., Caugant, D. A., Carlos, J., Ceyhan, M., Christensen, H., Climent, Y., Wals, P. D., Dinleyici, E. Ç., et al. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1557520 · Cited by 194
Self-citation
The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology
Masignani, V., Pizza, M., & Moxon, E. R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00751 · Cited by 168
Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational study
Bertran, M., Andrews, N. J., Davison, C., Dugbazah, B., Boateng, J. O., Lunt, R., Hardstaff, J., Green, M., Blomquist, P. B., Turner, C., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00057-9 · Cited by 155
Self-citation
Vaccines against Meningococcal Diseases
Pizza, M., Bekkat-Berkani, R., & Rappuoli, R. (2020) · Microorganisms · doi:10.3390/microorganisms8101521 · Cited by 151
Update on community-acquired bacterial meningitis: guidance and challenges
van Ettekoven, C. N., van de Beek, D., & Brouwer, M. C. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.04.019 · Cited by 118
Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy
Long, Q., Zheng, P., Zheng, X. W., Li, W., Hua, L., Yang, Z., Huang, W., & Ma, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114321 · Cited by 114
A Vaccine Against Group B Streptococcus: Recent Advances
Carreras‐Abad, C., Ramkhelawon, L., Heath, P. T., & Doaré, K. L. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s203454 · Cited by 113
Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study
Wang, B., Giles, L. C., Andraweera, P. H., McMillan, M., Almond, S., Beazley, R., Mitchell, J., Lally, N., Ahoure, M., Denehy, E., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00754-4 · Cited by 105
Epidemiology of community-acquired bacterial meningitis
Brouwer, M. C., & van de Beek, D. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000417 · Cited by 102
Restricted fluid bolus volume in early septic shock: results of the Fluids in Shock pilot trial
Inwald, D. P., Canter, R. R., Woolfall, K., Mouncey, P., Zenasni, Z., O’Hara, C., Carter, A., Jones, N., Lyttle, M. D., Nadel, S., et al. (2018) · Archives of Disease in Childhood · doi:10.1136/archdischild-2018-314924 · Cited by 99
Meningococcal B vaccine (4CMenB): the journey from research to real world experience
Rappuoli, R., Pizza, M., Masignani, V., & Vadivelu, K. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1547637 · Cited by 93
Invasive Meningococcal Disease in the Vaccine Era
Nadel, S., & Ninis, N. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00321 · Cited by 91
Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: A systematic review and meta-analysis
Pormohammad, A., Abasi, E., Azimi, T., Hosseini, S. S., Safari, H., Nasiri, M. J., & Fooladi, A. A. I. (2019) · Microbial Pathogenesis · doi:10.1016/j.micpath.2019.103571 · Cited by 90
Progress toward the global control of Neisseria meningitidis : 21st century vaccines, current guidelines, and challenges for future vaccine development
Dretler, A. W., Rouphael, N., & Stephens, D. S. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1451810 · Cited by 87
Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide
Muzzi, A., Brozzi, A., Serino, L., Bodini, M., Abad, R., Caugant, D. A., Comanducci, M., de Lemos, A. P. S., Gorla, M. C., Křížová, P., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2018.12.061 · Cited by 87
Self-citation
Emergency Meningococcal ACWY Vaccination Program for Teenagers to Control Group W Meningococcal Disease, England, 2015–2016
Campbell, H. J., Edelstein, M. L., Andrews, N. J., Borrow, R., Ramsay, M. E., & Ladhani, S. N. (2017) · Emerging infectious diseases · doi:10.3201/eid2307.170236 · Cited by 85
Self-citation
Meningococcal disease surveillance in the Asia–Pacific region (2020): The global meningococcal initiative
Aye, A. M. M., Bai, X., Borrow, R., Bory, S., Carlos, J., Caugant, D. A., Chiou, C., Dai, V. T. T., Dinleyici, E. Ç., Ghimire, P., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.07.025 · Cited by 81
Self-citation
First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England
Ladhani, S. N., Campbell, H. J., Andrews, N. J., Parikh, S. R., White, J. M., Edelstein, M. L., Clark, S. A., Lucidarme, J., Borrow, R., & Ramsay, M. E. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1244 · Cited by 80
Self-citation
Impact of meningococcal group B OMV vaccines, beyond their brief
Petousis‐Harris, H. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1381810 · Cited by 80
Meningococcal disease, a clinical and epidemiological review
Siqueira‐Batista, R., Gomes, A. P., Gazineo, J. L. D., Miguel, P. S. B., Santana, L. A., Oliveira, L., & Geller, M. (2017) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2017.10.004 · Cited by 77
Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada
Wals, P. D., Deceuninck, G., Lefebvre, B., Tsang, R. S. W., Law, D. K. S., Serres, G. D., Gîlca, V., Gilca, R., & Boulianne, N. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix154 · Cited by 74
Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children
Castilla, J., Cenoz, M. G., Abad, R., Sánchez-Cambronero, L., Lorusso, N., Izquierdo, C., Llabrés, S. C., Roig, J., Malvar, A., Carril, F. G., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2206433 · Cited by 71
Meningococcal disease in the Middle East and Africa: Findings and updates from the Global Meningococcal Initiative
Borrow, R., Caugant, D. A., Ceyhan, M., Christensen, H., Dinleyici, E. Ç., Findlow, J., Glennie, L., von Gottberg, A., Kechrid, A., Moreno, J. V., et al. (2017) · Journal of Infection · doi:10.1016/j.jinf.2017.04.007 · Cited by 68
Self-citation
Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018)
Azzari, C., Moriondo, M., Nieddu, F., Guarnieri, V., Lodi, L., Canessa, C., Indolfi, G., Giovannini, M., Napoletano, G., Russo, F., et al. (2020) · Vaccines · doi:10.3390/vaccines8030469 · Cited by 68
Serocorrelates of protection against infant group B streptococcus disease
Doaré, K. L., Kampmann, B., Vekemans, J., Heath, P. T., Goldblatt, D., Nahm, M. H., Baker, C. J., Edwards, M. S., Kwatra, G., Andrews, N. J., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30659-5 · Cited by 68
Self-citation
Emerging experience with meningococcal serogroup B protein vaccines
Toneatto, D., Pizza, M., Masignani, V., & Rappuoli, R. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1308828 · Cited by 67
Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007–08 and 2014–15: a qualitative and quantitative assessment
Parikh, S. R., Newbold, L. S., Slater, S., Stella, M., Moschioni, M., Lucidarme, J., Paola, R. D., Giuliani, M., Serino, L., Gray, S. J., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30170-6 · Cited by 66
Self-citation
Association of Use of a Meningococcus Group B Vaccine With Group B Invasive Meningococcal Disease Among Children in Portugal
Rodrigues, F. M. P., Marlow, R. D., Simões, M. J., Danon, L., Ladhani, S. N., & Finn, A. H. R. (2020) · JAMA · doi:10.1001/jama.2020.20449 · Cited by 63
Self-citation
Proteome‐minimized outer membrane vesicles from Escherichia coli as a generalized vaccine platform
Zanella, I., König, E., Tomasi, M., Gagliardi, A., Frattini, L. F., Fantappiè, L., Irene, C., Zerbini, F., Caproni, E., Isaac, S. J., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12066 · Cited by 63
Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis
Flacco, M. E., Manzoli, L., Rosso, A., Marzuillo, C., Bergamini, M., Stefanati, A., Cultrera, R., Villari, P., Ricciardi, W., Ioannidis, J. P. A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30048-3 · Cited by 62
Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch
Deceuninck, G., Lefebvre, B., Tsang, R. S. W., Betala-Belinga, J.-F., Serres, G. D., & Wals, P. D. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.06.021 · Cited by 62
Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study
Bryan, P. T., Seabroke, S., Wong, J., Donegan, K. L., Webb, E., Goldsmith, C., Vipond, C., & Feavers, I. M. (2018) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30103-2 · Cited by 61
Meningococcal disease and control in China: Findings and updates from the Global Meningococcal Initiative (GMI)
Li, J., Shao, Z., Liu, G., Bai, X., Borrow, R., Chen, M., Guo, Q., Han, Y., Li, Y., Taha, M., et al. (2018) · Journal of Infection · doi:10.1016/j.jinf.2018.01.007 · Cited by 59
Self-citation
Invasive meningococcal disease in patients with complement deficiencies: a case series (2008–2017)
Ladhani, S. N., Campbell, H. J., Lucidarme, J., Gray, S. J., Parikh, S. R., Willerton, L., Clark, S. A., Lekshmi, A., Walker, A., Patel, S. R., et al. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4146-5 · Cited by 58
Self-citation
Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines
Villena, R., Sáfadi, M. A. P., Valenzuela, M. T., Torres, J. P., Finn, A. H. R., & O’Ryan, M. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1458175 · Cited by 58
The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations
Vekemans, J., Crofts, J., Baker, C. J., Goldblatt, D., Heath, P. T., Madhi, S. A., Doaré, K. L., Andrews, N. J., Pollard, A. J., Saha, S. K., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.039 · Cited by 58
Self-citation
4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation
Wang, B., Giles, L. C., Andraweera, P. H., McMillan, M., Almond, S., Beazley, R., Mitchell, J., Ahoure, M., Denehy, E., Flood, L., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.05.021 · Cited by 57
The threat of meningococcal disease during the Hajj and Umrah mass gatherings: A comprehensive review
Yezli, S. (2018) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2018.05.003 · Cited by 64
Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine
Nolan, T. M., Santolaya, M. E., de Looze, F. J., Marshall, H. S., Richmond, P., Henein, S., Rheault, P., Heaton, K., Perrett, K. P., Garfield, H., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2018.12.059 · Cited by 52
A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines
Findlow, J., Balmer, P., & Borrow, R. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1593082 · Cited by 51
Self-citation
Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial
Martinón‐Torres, F., Sáfadi, M. A. P., Martínez, A. C., Marquez, P. I., Torres, J. C. T., Weckx, L. Y., Moreira, E. D., Mensi, I., Calabresi, M., & Toneatto, D. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.05.023 · Cited by 50
A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health
Biselli, R., Nisini, R., Lista, F. R., Autore, A., Lastilla, M., Lorenzo, G. D., Peragallo, M. S., Stroffolini, T., & D’Amelio, R. (2022) · Biomedicines · doi:10.3390/biomedicines10082050 · Cited by 48
Epidemiology, clinical presentation, risk factors, intensive care admission and outcomes of invasive meningococcal disease in England, 2010–2015
Parikh, S. R., Campbell, H. J., Gray, S. J., Beebeejaun, K., Ribeiro, S., Borrow, R., Ramsay, M. E., & Ladhani, S. N. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.038 · Cited by 47
Self-citation
Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK
Ladhani, S. N., White, P. J., Campbell, H., Mandal, S., Borrow, R., Andrews, N. J., Bhopal, S., Saunders, J., Mohammed, H. P., Drisdale-Gordon, L., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00031-8 · Cited by 49
Self-citation
Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States
Rajam, G., Stella, M., Kim, E., Paulos, S., Boccadifuoco, G., Serino, L., Carlone, G. M., & Medini, D. (2017) · mSphere · doi:10.1128/msphere.00261-17 · Cited by 46
Inhibitors of the Neisseria meningitidis PilF ATPase provoke type IV pilus disassembly
Aubey, F., Corre, J., Kong, Y., Xu, X., Obino, D., Goussard, S., Lapeyrere, C., Souphron, J., Couturier, C., Renard, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817757116 · Cited by 46
Herd Protection against Meningococcal Disease through Vaccination
Clark, S. A., & Borrow, R. (2020) · Microorganisms · doi:10.3390/microorganisms8111675 · Cited by 45
Self-citation
Epidemiology of invasive meningococcal B disease in Australia, 1999–2015: priority populations for vaccination
Archer, B. N., Chiu, C. K., Jayasinghe, S. H., Richmond, P., McVernon, J., Lahra, M. M., Andrews, R. M., & McIntyre, P. B. (2017) · The Medical Journal of Australia · doi:10.5694/mja16.01340 · Cited by 44
Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination
Martinón‐Torres, F., Banzhoff, A., Azzari, C., Wals, P. D., Marlow, R. D., Marshall, H. S., Pizza, M., Rappuoli, R., & Bekkat-Berkani, R. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.04.031 · Cited by 42
Vaccination strategies for the prevention of meningococcal disease
Vuocolo, S. C., Balmer, P., Gruber, W. C., Jansen, K. U., Anderson, A. S., Perez, J. L., & York, L. J. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1451287 · Cited by 42
Vaccine Evolution and Its Application to Fight Modern Threats
Andreano, E., D’Oro, U., Rappuoli, R., & Finco, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01722 · Cited by 42
Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe
Bai, X., Borrow, R., Bukovski, S., Caugant, D. A., Culic, D., Delic, S., Dinleyici, E. Ç., Eloshvili, M., Erdősi, T., Galajeva, J., et al. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.10.018 · Cited by 41
Self-citation
Protection Against Invasive Infections in Children Caused by Encapsulated Bacteria
Sadarangani, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02674 · Cited by 39
Prevalence of Neisseria meningitidis serogroups in invasive meningococcal disease in China, 2010 - 2020: a systematic review and meta-analysis
Xu, J., Chen, Y., Yue, M., Yu, J., Han, F., Xu, L., & Shao, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2071077 · Cited by 38
Recent Progress in the Prevention of Serogroup B Meningococcal Disease
Feavers, I. M., & Maiden, M. C. J. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00566-16 · Cited by 36
Human genetics of meningococcal infections
Hodeib, S., Herberg, J. A., Levin, M., & Sancho‐Shimizu, V. (2020) · Human Genetics · doi:10.1007/s00439-020-02128-4 · Cited by 36
Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents – Results from a randomized, controlled, observer-blind phase II study
Welsch, J. A., Senders, S. D., Essink, B. J., Klein, T., Smolenov, I. V., Pedotti, P., Barbi, S., Verma, B., & Toneatto, D. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.07.016 · Cited by 36
Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B
Calle, I. R., Raguindin, P. F., Rial, J. G., Rodrı́guez-Tenreiro, C., & Martinón‐Torres, F. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s159952 · Cited by 34
Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience
Isitt, C. E., Cosgrove, C. A., Ramsay, M. E., & Ladhani, S. N. (2020) · Archives of Disease in Childhood · doi:10.1136/archdischild-2019-318047 · Cited by 34
Self-citation
The Use of Quasi-experimental Designs for Vaccine Evaluation
Bernal, J. L., Andrews, N. J., & Amirthalingam, G. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy906 · Cited by 33
Self-citation
Monocyte-activation test to reliably measure the pyrogenic content of a vaccine: An in vitro pyrogen test to overcome in vivo limitations
Valentini, S. B., Santoro, G., Baffetta, F., Franceschi, S., Paludi, M., Brandini, E., Gherardini, L., Serruto, D., & Capecchi, B. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.10.082 · Cited by 33
Monitoring the COVID-19 immunisation programme through a national immunisation Management system – England’s experience
Tessier, E., Stowe, J., Tsang, C., Rai, Y., Clarke, E., Lakhani, A., Makwana, A., Heard, H., Rickeard, T., Kirsebom, F., et al. (2022) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2022.104974 · Cited by 32
Self-citation
Antibody persistence and booster responses 24–36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial
Martinón‐Torres, F., Martínez, A. C., Simkó, R., Marquez, P. I., Arimany, J.-L., Giménez‐Sánchez, F., Gianzo, J. A. C., Kovacs, E. M. R., Rojo, P., Wang, H., et al. (2017) · Journal of Infection · doi:10.1016/j.jinf.2017.12.005 · Cited by 31
Engineered Remolding and Application of Bacterial Membrane Vesicles
Li, Q., Rao, Y., Zhu, K., Rao, X., & Zhou, R. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.729369 · Cited by 32
Critical care management of infectious meningitis and encephalitis
Meyfroidt, G., Kurtz, P., & Sonneville, R. (2020) · Intensive Care Medicine · doi:10.1007/s00134-019-05901-w · Cited by 30
Invasive Meningococcal Disease, 2011–2020, and Impact of the COVID-19 Pandemic, England
Subbarao, S., Campbell, H. J., Ribeiro, S., Clark, S. A., Lucidarme, J., Ramsay, M. E., Borrow, R., & Ladhani, S. N. (2021) · Emerging infectious diseases · doi:10.3201/eid2709.204866 · Cited by 29
Self-citation
B Part of It protocol: a cluster randomised controlled trial to assess the impact of 4CMenB vaccine on pharyngeal carriage of Neisseria meningitidis in adolescents
Marshall, H. S., McMillan, M., Koehler, A. P., Lawrence, A. J., MacLennan, J. M., Maiden, M. C. J., Ramsay, M. E., Ladhani, S. N., Trotter, C. L., Borrow, R., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020988 · Cited by 28
Self-citation
Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults
Martinón‐Torres, F., Nolan, T. M., Toneatto, D., & Banzhoff, A. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1627159 · Cited by 28
The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae
Rubin, D. H. F., Ross, J. D. C., & Grad, Y. H. (2020) · Translational research · doi:10.1016/j.trsl.2020.02.002 · Cited by 27
Vaccine Candidates for the Control and Prevention of the Sexually Transmitted Disease Gonorrhea
Haese, E. C., Thai, V. C., & Kahler, C. M. (2021) · Vaccines · doi:10.3390/vaccines9070804 · Cited by 27
Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults
Leeds, I. L., Namasivayam, V., Bamogo, A., Sankhla, P., & Thayer, W. M. (2018) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2018.09.020 · Cited by 27
Correlates of protection for meningococcal surface protein vaccines: lessons from the past
Findlow, J., Lucidarme, J., Taha, M., Burman, C., & Balmer, P. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1940144 · Cited by 26
First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia
Marshall, H. S., Lally, N., Flood, L., & Phillips, P. A. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50481 · Cited by 25
Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine
Lujan, E., Partridge, E., Giuntini, S., Ram, S., & Granoff, D. M. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00121-17 · Cited by 24
Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK
Ladhani, S. N., Andrews, N. J., & Ramsay, M. E. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30492-8 · Cited by 24
Self-citation
A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB)
Marshall, G. S., Abbing‐Karahagopian, V., Marshall, H. S., Cenci, S., Conway, J. H., Occhipinti, E., Bekkat-Berkani, R., Banzhoff, A., & Sohn, W.-Y. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2222015 · Cited by 24
Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus
Lujan, E., Winter, K., Rovaris, J., Liu, Q., & Granoff, D. M. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix519 · Cited by 24
Genomic Surveillance of 4CMenB Vaccine Antigenic Variants among Disease-Causing Neisseria meningitidis Isolates, United Kingdom, 2010–2016
Rodrigues, C. M. C., Lucidarme, J., Borrow, R., Smith, A. H., Cameron, J. C., Moxon, E. R., & Maiden, M. C. J. (2018) · Emerging infectious diseases · doi:10.3201/eid2404.171480 · Cited by 24
Self-citation
Neisseria meningitidis and meningococcal disease: recent discoveries and innovations
Read, R. C. (2019) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000606 · Cited by 24
Profiling IgG and IgA antibody responses during vaccination and infection in a high-risk gonorrhoea population
Stejskal, L., Thistlethwaite, A., Bencomo, F. R., Rashmi, S., Harrison, O. B., Feavers, I. M., Maiden, M. C. J., Jerse, A. E., Barnes, G., Chirro, O., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51053-x · Cited by 23
Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices
Sohn, W.-Y., Tahrat, H., Novy, P., & Bekkat-Berkani, R. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2021881 · Cited by 23
Psychological interventions as vaccine adjuvants: A systematic review
Vedhara, K., Ayling, K., Sunger, K., Caldwell, D. M., Halliday, V., Fairclough, L. C., Avery, A. J., Robles, L. A., Garibaldi, J. M., Welton, N. J., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.091 · Cited by 23
The recommended lifetime immunization schedule from the board of vaccination calendar for life in Italy: A continuing example of impact on public health policies
Bonanni, P., Villani, A., Scotti, S., Biasci, P., Russo, R., Maio, T., Rosati, G. V., Moscadelli, A., Conforti, G., Azzari, C., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.01.019 · Cited by 28
Crystal structure reveals vaccine elicited bactericidal human antibody targeting a conserved epitope on meningococcal fHbp
López‐Sagaseta, J., Beernink, P. T., Bianchi, F., Santini, L., Frigimelica, E., Lucas, A. H., Pizza, M., & Bottomley, M. J. (2018) · Nature Communications · doi:10.1038/s41467-018-02827-7 · Cited by 23
Challenges and opportunities for meningococcal vaccination in the developing world
Shaker, R., Fayad, D., & Dbaibo, G. S. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1434463 · Cited by 24
Trends in laboratory-confirmed bacterial meningitis (2012–2019): national observational study, England
Subbarao, S., Ribeiro, S., Campbell, H. J., Okike, I. O., Ramsay, M. E., & Ladhani, S. N. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100692 · Cited by 22
Self-citation
Proteomics, Bioinformatics and Structure-Function Antigen Mining For Gonorrhea Vaccines
Baarda, B. I., Martinez, F. G., & Sikora, A. E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02793 · Cited by 22
Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials
Zafack, J. G., Bureau, A., Skowronski, D. M., & Serres, G. D. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026953 · Cited by 22
TIPICO IX: report of the 9th interactive infectious disease workshop on infectious diseases and vaccines
Martinón‐Torres, F., Bosch, X. F., Rappuoli, R., Ladhani, S. N., Redondo, E., Vesikari, T., García‐Sastre, A., Calle, I. R., Rial, J. G., Salas, A., et al. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1609823 · Cited by 21
Self-citation
NadA3 Structures Reveal Undecad Coiled Coils and LOX1 Binding Regions Competed by Meningococcus B Vaccine-Elicited Human Antibodies
Liguori, A., Iacono, L. D., Maruggi, G., Benucci, B., Merola, M., Surdo, P. L., López‐Sagaseta, J., Pizza, M., Malito, E., & Bottomley, M. J. (2018) · mBio · doi:10.1128/mbio.01914-18 · Cited by 21
Evaluating the Effectiveness of Vaccines Using a Regression Discontinuity Design
Basta, N. E., & Halloran, M. E. (2019) · American Journal of Epidemiology · doi:10.1093/aje/kwz043 · Cited by 21
Using Omics Technologies and Systems Biology to Identify Epitope Targets for the Development of Monoclonal Antibodies Against Antibiotic-Resistant Bacteria
Martín-Galiano, A. J., & McConnell, M. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02841 · Cited by 21
Pneumococcal Choline-Binding Proteins Involved in Virulence as Vaccine Candidates
Sempere, J., Llamosí, M., Menéndez, I. D. R., Ruiz, B. L., Domenech, M., & González‐Camacho, F. (2021) · Vaccines · doi:10.3390/vaccines9020181 · Cited by 22
Clinical and regulatory development strategies for GBS vaccines intended for maternal immunisation in low- and middle-income countries
Doaré, K. L., Benassi, V., Cavaleri, M., Enwere, G., Giersing, B. K., Goldblatt, D., Heath, P. T., Hombach, J., Isbrucker, R. A., Karampatsas, K., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127131 · Cited by 20
Long-Term Protection Against Invasive Meningococcal B Disease and Gonococcal Infection 5 Years After Implementation of Funded Childhood and Adolescent 4CMenB Vaccination Program in South Australia: An Observational Cohort and Case-Control Study
Wang, B., Giles, L. C., Andraweera, P. H., McMillan, M., Beazley, R., Almond, S., Lally, N., Bell, C., Flood, L., Ward, J. S., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf372 · Cited by 20
Four-Component Recombinant Protein–Based Vaccine Effectiveness Against Serogroup B Meningococcal Disease in Italy
Lodi, L., Barbati, F., Amicizia, D., Baldo, V., Barbui, A. M., Bondi, A., Costantino, C., Dalt, L. D., Ferrara, L., Fortunato, F., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.29678 · Cited by 20
Self-citation

Authors: Parikh, S. R., Andrews, N. J., Beebeejaun, K., Campbell, H., Ribeiro, S., Ward, C., White, J. M., Borrow, R., Ramsay, M. E., & Ladhani, S. N.
Affiliations: Public Health England (GB)
Corresponding author: Ladhani, Shamez N
ORCID: Parikh, Sydel R
Andrews, Nick J
Beebeejaun, Kazim
Campbell, Helen
Ribeiro, Sonia
Ward, Charlotte
White, Joanne M
Borrow, Ray
Ramsay, Mary E
Ladhani, Shamez N
Venue: The Lancet
Publisher: Elsevier BV
Published: 2016-12
Volume: 388
Issue: 10061
Pages: 2775-2782
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(16)31921-3
OpenAlex: W2540474236
Cited by: 275
References: 18
Citations by year: 2026: 10 · 2025: 11 · 2024: 14 · 2023: 14 · 2022: 15 · 2021: 20 · 2020: 38 · 2019: 63 · 2018: 53 · 2017: 35 · 2016: 1
FWCI: 51.87
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
St George's Online Research Archive (St George's University of London) (acceptedVersion)
Funders: Public Health England
Topics: Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal and Maternal Infections
Life Sciences › Immunology and Microbiology › Microbiology › Microbial infections and disease research
Keywords: 4CMenB, infant vaccination schedule, catch-up vaccination, meningococcal disease incidence, vaccination coverage, meningococcal serogroups, national vaccination program, disease surveillance, vaccine impact, meningococcal serogroup B
MeSH terms: United Kingdom, Humans, Immunization Schedule, Infant, Meningococcal Infections, Public Health, Treatment Outcome, Immunization Programs, Meningococcal Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks